Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics

Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics: Efficacy Study in Adults and Children. Randomized Prospective Study With Direct Individual Benefit

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00181012

Enrollment

100

Registered

2005-09-16

Start date

2005-05-31

Completion date

Unknown

Last updated

2007-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Pain

Keywords

Cancer Related Visceral Pain Resistant to Morphinics

Brief summary

This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.

Interventions

DRUGLidocaine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

6 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy * Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults) * Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis * Pain resistant to morphinic treatment

Exclusion criteria

* Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months * Neurological: non-controlled epilepsy, encephalopathy, or dementia * Severe hepatic insufficiency * Severe renal insufficiency * Respiratory insufficiency * Patients having surgery or in postoperative period * Known deficit in G6PD, alanine exposure, or sulphamide treatment * Porphyria * Weight \> 80 kg

Design outcomes

Primary

Measure	Time frame
To determine prospectively the lidocaine efficacy in 2 types of patient populations with cancer (group A: children from 6 to 14 years old and group B: adults from 15 to 70 years old)	continuous intravenous perfusion for 6 days

Secondary

Measure	Time frame
To confirm the tolerance of the lidocaine	—

Countries

France

Contacts

Primary ContactPhilippe Poulain, MD

poulain@igr.fr33 1 42 11 40 53

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026